Home / Market News / $AMGN
benzinga Corporate Catalyst Impact 75/100 ● positive

Amgen, AstraZeneca Announces Data From Phase 3 CROSSING Study Demonstrated TEZSPIRE Showed Histologic Remission For 64.8% For 210 Mg Dose At Week 24; TEZSPIRE Also Reduced Frequency, Severity Of Dysphagia Symptoms 18.8 Points

Oct 20, 2026, 1:07 PM UTC · Primary ticker $AMGN

Amgen and AstraZeneca announced positive full results from their Phase 3 CROSSING trial for TEZSPIRE in eosinophilic esophagitis (EoE). The drug demonstrated statistically significant improvements in histologic remission and reduced dysphagia symptoms, indicating strong efficacy for a new therapeutic option.

Amgen and AstraZeneca announced full positive results from their Phase 3 CROSSING trial for TEZSPIRE in treating eosinophilic esophagitis (EoE). The trial showed TEZSPIRE achieved high rates of histologic remission (64.8% for 210mg dose) and significantly reduced dysphagia symptoms compared to placebo. This is a significant positive development for both companies as it validates the efficacy of TEZSPIRE in a new indication, potentially expanding its market. For traders, this presents a short-term opportunity for AMGN and AZN as the positive data could lead to increased investor confidence and potential future revenue growth from this expanded use. The long-term implication is a stronger competitive position in the immunology market, though regulatory approval and market adoption remain key factors.

$AMGN positive Positive clinical trial results for key drug
$AZN positive Positive clinical trial results for key drug
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.